Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomised controlled study

Schering-Plough AS (Norway)0 个研究点目标入组 663 人开始时间: 2005年2月1日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Patients 18 years or above with a minimum of two years history of SAR confirmed by either a positive skin prick test or a positive serologic allergen test to the relevant seasonal allergen
•2. Clinically symptomatic with SAR at baseline/inclusion with a minimum total nasal symptom score (rhinorrhoea, congestion, itching and sneezing) of at least 6 and rhinorrhoea being minimum 2 (moderate)
•3. Willingness to adhere to dosing and visit schedule
•4. Females of childbearing potential have to use medically accepted methods of birth control
•5. Written informed consent

•1. Pulmonary disease, perennial rhinitis, sinusitis, rhinitis medicamentosa, pollen desensitisation during the last 6 months
•2. Respiratory tract infection within the last two weeks
•3. Structural nasal abnormalities (including polyps)
•4. Use of oral, nasal, ocular decongestants, corticosteroids in any form (except mild dermatological group I corticosteroids allowed in only small areas), other antihistamines (oral or topical), any investigational drug during the last 30 days
•5. Pregnant or nursing females

发起方

Schering-Plough AS (Norway)